NEWARK, Calif., June 18, 2021 /PRNewswire/ -- Protagonist
Therapeutics, Inc. (Nasdaq:PTGX), a clinical stage
biopharmaceutical company, today announced the closing of its
previously announced underwritten public offering of 3,503,311
shares of its common stock, including 456,953 shares sold pursuant
to the underwriters' exercise in full of their "green shoe" option
to purchase additional shares, at a price to the public of
$37.75 per share. Aggregate gross
proceeds to Protagonist from the offering were approximately
$132.2 million, before deducting
underwriting discounts and commissions and offering expenses.
J.P. Morgan Securities LLC, Jefferies LLC and Piper Sandler acted as joint book-running
managers for the offering. JMP Securities LLC and H.C. Wainwright
& Co., LLC acted as co-lead managers for the offering.
A shelf registration statement relating to the offered shares of
common stock was filed with the Securities and Exchange Commission
(SEC) on December 10, 2020. A final
prospectus supplement and accompanying prospectus relating to the
offering have been filed with the SEC and is available on the SEC's
website, located at www.sec.gov. Copies of the final prospectus
supplement and the accompanying prospectus related to the offering
may be obtained, when available, from J.P. Morgan Securities LLC,
c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, New York 11717, by
telephone at 866-803-9204, or by email at
prospectus-eq_fi@jpmchase.com; Jefferies LLC (Attention: Equity
Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor,
New York, New York 10022;
telephone: 877-821-7388; email:
Prospectus_Department@Jefferies.com); or Piper Sandler & Co., Attention: Prospectus
Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800)
747-3924 or by email at prospectus@psc.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of,
these securities in any state or jurisdiction in which such offer,
solicitation, or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/protagonist-therapeutics-inc-announces-closing-of-132-2-million-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares-301315628.html
SOURCE Protagonist Therapeutics, Inc.